WDR4 Promotes the Progression and Lymphatic Metastasis of Bladder Cancer Via Transcriptional Down-Regulation of ARRB2.

Guoli Wang,Xin He,Huiqi Dai,Lingyi Lin,Wenmin Cao,Yao Fu,Wenli Diao,Meng Ding,Qing Zhang,Wei Chen,Hongqian Guo
DOI: https://doi.org/10.1038/s41389-023-00493-z
2023-01-01
Oncogenesis
Abstract:Lymph node (LN) metastasis is one of the key prognostic factors in bladder cancer, but its underlying mechanisms remain unclear. Here, we found that elevated expression of WD repeat domain 4 (WDR4) in bladder cancer correlated with worse prognosis. WDR4 can promote the LN metastasis and proliferation of bladder cancer cells. Mechanistic studies showed that WDR4 can promote the nuclear localization of DEAD-box helicase 20 (DDX20) and act as an adaptor to bind DDX20 and Early growth response 1 (Egr1), thereby inhibiting Egr1-promoted transcriptional expression of arrestin beta 2 (ARRB2) and ultimately contributing to the progression of bladder cancer. Immunohistochemical analysis confirmed that WDR4 expression is also an independent predictor of LN metastasis in bladder cancer. Our results reveal a novel mechanism of LN metastasis and progression in bladder cancer and identify WDR4 as a potential therapeutic target for metastatic bladder cancer.
What problem does this paper attempt to address?